Display options
Cite
Mastoris I, Tonna JE, Hu J, et al. Use of Extracorporeal Membrane Oxygenation as Bridge to Replacement Therapies in Cardiogenic Shock: Insights From the Extracorporeal Life Support Organization. Circ Heart Fail. 2021;CIRCHEARTFAILURE121008777doi: 10.1161/CIRCHEARTFAILURE.121.008777.
Mastoris, I., Tonna, J. E., Hu, J., Sauer, A. J., Haglund, N. A., Rycus, P., Wang, Y., Wallisch, W. J., Abicht, T. O., Danter, M. R., Tedford, R. J., Fang, J. C., & Shah, Z. (2021). Use of Extracorporeal Membrane Oxygenation as Bridge to Replacement Therapies in Cardiogenic Shock: Insights From the Extracorporeal Life Support Organization. Circulation. Heart failure, CIRCHEARTFAILURE121008777. https://doi.org/10.1161/CIRCHEARTFAILURE.121.008777
Mastoris, Ioannis, et al. "Use of Extracorporeal Membrane Oxygenation as Bridge to Replacement Therapies in Cardiogenic Shock: Insights From the Extracorporeal Life Support Organization." Circulation. Heart failure vol. (2021): CIRCHEARTFAILURE121008777. doi: https://doi.org/10.1161/CIRCHEARTFAILURE.121.008777
Mastoris I, Tonna JE, Hu J, Sauer AJ, Haglund NA, Rycus P, Wang Y, Wallisch WJ, Abicht TO, Danter MR, Tedford RJ, Fang JC, Shah Z. Use of Extracorporeal Membrane Oxygenation as Bridge to Replacement Therapies in Cardiogenic Shock: Insights From the Extracorporeal Life Support Organization. Circ Heart Fail. 2021 Dec 09;CIRCHEARTFAILURE121008777. doi: 10.1161/CIRCHEARTFAILURE.121.008777. Epub 2021 Dec 09. PMID: 34879706.
Copy Download .nbib Format: NLM
Share it on

Circ Heart Fail. 2021 Dec 09;CIRCHEARTFAILURE121008777. doi: 10.1161/CIRCHEARTFAILURE.121.008777. Epub 2021 Dec 09.

Use of Extracorporeal Membrane Oxygenation as Bridge to Replacement Therapies in Cardiogenic Shock: Insights From the Extracorporeal Life Support Organization.

Circulation. Heart failure

Ioannis Mastoris, Joseph E Tonna, Jinxiang Hu, Andrew J Sauer, Nicholas A Haglund, Peter Rycus, Yu Wang, William J Wallisch, Travis O Abicht, Matthew R Danter, Ryan J Tedford, James C Fang, Zubair Shah

Affiliations

  1. Department of Cardiovascular Medicine, University of Kansas Health System, University of Kansas School of Medicine, Kansas City. (I.M., A.J.S., N.A.H., Z.S.).
  2. Division of Cardiothoracic Surgery (J.E.T.).
  3. Division of Emergency Medicine (J.E.T.).
  4. Department of Biostatistics, University of Kansas Health System, University of Kansas School of Medicine, Kansas City. (J.H., Y.W.).
  5. Department of Surgery, University of Utah Health, Salt Lake City. Extracorporeal Life Support Organization, Ann Arbor, MI (P.R.).
  6. Department of Anesthesiology, University of Kansas Health System, University of Kansas School of Medicine, Kansas City. (W.J.W.).
  7. Department of Cardiothoracic Surgery, University of Kansas Health System, University of Kansas School of Medicine, Kansas City. (T.O.A., M.R.D.).
  8. Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston (R.J.T.).
  9. Division of Cardiovascular Medicine, University of Utah, Salt Lake City (J.C.F.).

PMID: 34879706 DOI: 10.1161/CIRCHEARTFAILURE.121.008777

Abstract

BACKGROUND: There has been increasing use of extracorporeal membrane oxygenation (ECMO) as bridge to heart transplant (orthotopic heart transplant [OHT]) or left ventricular assist device (LVAD) over the last decade. We aimed to provide insights on the population, outcomes, and predictors for the selection of each therapy.

METHODS: Using the Extracorporeal Life Support Organization Registry between 2010 and 2019, we compared in-hospital mortality and length of stay, predictors of OHT versus LVAD, and predictors of in-hospital mortality for patients with cardiogenic shock that were bridged with ECMO to OHT or LVAD. One hundred sixty-seven patients underwent LVAD versus 234 patients who underwent OHT.

RESULTS: The overall use of ECMO has increased from 1.7% in 2010 to 22.2% in 2019. Mortality was similar between groups (LVAD: 28.7% versus OHT: 29.1%) while length of stay was longer for OHT (LVAD: 49.6 versus OHT: 59.5 days,

CONCLUSIONS: ECMO use as a bridge to advanced therapies has increased over time, with more patients undergoing LVAD than OHT. Mortality was equal between the 2 groups while length of stay was longer for OHT.

Keywords: extracorporeal membrane oxygenation; heart-assisted devices; length of stay; mortality; shock, cardiogenic; transplant

Publication Types